WALTHAM, Mass. & STOCKHOLM--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced that results from the Kids B-LONG Phase 3 clinical trial, which studied ALPROLIX® Coagulation Factor IX (Recombinant), Fc Fusion Protein in previously-treated children with severe hemophilia B, were published in The Lancet Haematology. The primary outcome measure of the trial was development of inhibitors, and no patients treated with ALPROLIX in the study developed inhibitors. Treatment was generally well tolerated and resulted in low bleeding rates in participants, most of whom remained on once-weekly dosing during the study. The manuscript, entitled “Recombinant Factor IX Fc Fusion Protein in Children with Haemophilia B (Kids B-LONG): Results from a Multicentre, Non-Randomised Phase 3 Study,” was published in the February 2017 issue of The Lancet Haematology.
“The Medical and Scientific Advisory Council of the National Hemophilia Foundation recommends that prophylaxis be considered the optimal treatment regimen for people with severe hemophilia B, and be initiated early based on the body of evidence demonstrating improved long-term clinical outcomes,” said Roshni Kulkarni, MD, Department of Pediatrics and Human Development, Michigan State University, East Lansing, Michigan, United States, and investigator in the study. “To date, Kids B-LONG is the largest study to evaluate the safety and efficacy of extended half-life factor IX therapy in children with hemophilia B, and the study’s results align with those in studies of ALPROLIX in adults and adolescents.”
Kids B-LONG investigated the safety, efficacy and pharmacokinetics (measurement of the presence of the drug in a person’s body over time) of ALPROLIX in previously treated children under the age of 12 with severe hemophilia B (n=30). The primary outcome measure was development of inhibitors (neutralizing antibodies that can interfere with the activity of the therapy). Secondary outcomes included pharmacokinetics, annualized bleeding rate (ABR), and the number of infusions required to resolve a bleed.
In this study, no participants developed inhibitors to ALPROLIX. ALPROLIX was well tolerated and adverse events (AEs) observed were typical of the pediatric hemophilia B population. The most common AEs were common cold (n=7, 23%) and fall (n=6, 20%). Four participants experienced serious AEs during the study, all of which were assessed as unrelated to ALPROLIX by the investigators. In the study, there were no reports of anaphylaxis or serious hypersensitivity reactions to ALPROLIX, no vascular thrombotic events, and no deaths.
Children (n=30) treated prophylactically with ALPROLIX had a median ABR of 2.0 overall and zero spontaneous joint bleeds. Of all patients treated, 10 of 30 (33%) experienced no bleeding episodes, and 19 of 30 (63%) reported no joint bleeding on-study. Overall, 92% of bleeding episodes were controlled by one or two infusions of ALPROLIX. Following a switch to ALPROLIX therapy, 80% of children extended their dosing interval compared to previous treatment, and nearly all remained on once-weekly prophylactic dosing throughout the study.
“These data in children reaffirm the well-characterized efficacy and safety profile of ALPROLIX as demonstrated in studies of adults and adolescents with hemophilia B, and they build on the robust real-world experience of ALPROLIX over more than two years,” said Maha Radhakrishnan, MD, senior vice president of medical at Bioverativ. “Together with Sobi, we are committed to advancing the care of people with hemophilia around the world.”
“Through Fc fusion technology, ALPROLIX uses the body’s natural pathway to prolong the time the therapy remains in the body,” said Krassimir Mitchev, MD, PhD, vice president and medical therapeutic area head of haemophilia at Sobi. “Along with Bioverativ, we are dedicated to furthering the study of real-world clinical use of ALPROLIX and continuing to explore the potential of Fc fusion technology to address the significant unmet needs that remain in hemophilia.”
About Kids B-LONG
Kids B-LONG was a global, open-label, multicenter Phase 3 study involving 30 boys under the age of 12 with severe hemophilia B (factor IX activity equal to or less than 2 IU per dL, or 2%) with at least 50 prior exposure days to factor IX therapies. To date, Kids B-LONG is the largest study to evaluate extended half-life factor IX therapy in children with hemophilia B. The study was conducted at 16 hemophilia treatment centers in Australia, Hong Kong, Ireland, the Netherlands, South Africa, the UK, and the United States. Overall, 27 participants (90%) completed the study. The median time participants spent in the study was 49.4 weeks, and 24 participants received ALPROLIX infusions on at least 50 separate days (exposure days).
ALPROLIX® Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant clotting factor therapy developed for hemophilia B using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling ALPROLIX to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). While Fc fusion technology has been used for more than 15 years, Bioverativ and Sobi have optimized the technology and are the first companies to utilize it in the treatment of haemophilia. ALPROLIX is manufactured using a human cell line in an environment free of animal and human additives.
ALPROLIX is approved and marketed by Bioverativ for the treatment of hemophilia B in the United States, Japan and Canada. It is also approved in Australia, New Zealand, Brazil and other countries, and Bioverativ has marketing rights in these regions. It is also authorised in the European Union, Iceland, Liechtenstein, Norway and Switzerland, where it is marketed by Sobi.
Allergic-type hypersensitivity reactions and development of inhibitors have been observed with ALPROLIX in the treatment of hemophilia B, including in previously untreated patients. For more information, please see the full U.S. prescribing information for ALPROLIX. Note that the indication for previously untreated patients is not included in the EU Product Information.
About Hemophilia B
Hemophilia B is caused by having substantially reduced or no factor IX activity, which is needed for normal blood clotting.1 The World Federation of Hemophilia estimates that approximately 28,000 people are currently diagnosed with hemophilia B worldwide.2
People with hemophilia B may experience bleeding episodes in joints and muscles that cause pain, decreased mobility and irreversible joint damage. In the worst cases, these bleeding episodes can cause organ bleeds and life-threatening hemorrhages. Infusions of factor IX temporarily replace clotting factors necessary to resolve bleeding and, when used prophylactically, to prevent new bleeding episodes.1
About the Bioverativ and Sobi Collaboration
Bioverativ and Sobi collaborate on the development and commercialization of ALPROLIX and ELOCTATE® Antihemophilic Factor (Recombinant), Fc Fusion Protein, which is marketed as Elocta® in Europe. Bioverativ has final development and commercialization rights in North America and all other regions in the world excluding the Sobi territory, and has manufacturing responsibility for ELOCTATE and ALPROLIX. Sobi has final development and commercialization rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets).
Bioverativ (NASDAQ: BIVV) is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.
Bioverativ was created as a spin-off from Biogen’s hemophilia business and separated from Biogen effective February 1, 2017. Bioverativ is an independent, publicly-traded company, headquartered in Waltham, Massachusetts. During a temporary transition period, which includes time to allow Bioverativ to establish certain licenses and consents related to ELOCTATE and ALPROLIX, each of Bioverativ and Biogen will have a relationship to the products.
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
Bioverativ Safe Harbor
This press release contains forward-looking statements, including statements about the potential benefits, safety profile, and efficacy of ALPROLIX in hemophilia B and the potential of the Fc Fusion technology. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause Bioverativ’s actual results to differ materially from those reflected in such statements, including, without limitation, risks related to development of early stage programs, unexpected concerns that may arise from additional data or analysis, regulatory authorities may require additional information or further studies, regulatory authorities may fail to expand product labeling, and other risks and uncertainties associated with Bioverativ’s drug development and commercialization activities described in the Risk Factors section of Bioverativ’s filings with the Securities and Exchange Commission. These statements are based on Bioverativ’s current beliefs and expectations and speak only as of the date of this press release. Bioverativ does not undertake any obligation to publicly update any forward-looking statements.
1 World Federation of Hemophilia. About Bleeding Disorders –
Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B.
Accessed on: January, 13, 2017.
2 World Federation of Hemophilia. Report on the Annual Global Survey 2013. Available at: http://www1.wfh.org/publications/files/pdf-1591.pdf. Accessed on: January 13, 2017.
Tracy Vineis, +1 781-663-4350
Investor Relations Contact:
Susan Altschuller, +1 781-663-4360
Linda Holmström, + 46 708 73 40 95
Investor Relations Contact:
Jörgen Winroth, +1 347-224-0819